Mabwell Established a Licensing and Commercialization Agreement of Adalimumab Biosimilar for Morocco Market

Release time:Jul 31, 2023

Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that it has established a licensing and commercialization agreement with Sothema, the biggest pharmaceutical company in Morocco, for its product Adalimumab Biosimilar. Under the agreement, Sothema is responsible for the local filling finish, registration and commercialization in Morrocco.

Mr. Huiguo Hu, Board Member and Senior Vice President of Mabwell, said, “We are pleased to build the strategic collaboration with Sothema for Morocco market, work together to local filling finish and commercialize adalimumab biosimilar in Morocco. Morocco is the important country in Africa for the business, it’s also the important country in the ‘Belt and Road Initiative’. This partnership represents another important step in our presence for Africa market, and we trust that it will further improve the accessibility of adalimumab to local patients in Morocco.”


About Sothema

Founded in 1976 in Morocco, the first pharmaceutical company in Morocco listed in Casablanca stock exchange in 2005. Sothema has 6 manufacturing units, more than 300 marketed products, around 1,000 employees, which is the biggest pharmaceutical company in Morocco. The production of licensed medicines for 35 multinational laboratories, world leaders in the pharmaceutical industry, is the main activity of Sothema. Sothema also specializes in manufacturing of generics in different types according to the highest standards. So far, Sothema exports the products to Europe, Maghreb, Sub-Saharan Africa and the Persian Gulf, and the products have a good reputation in many countries.